Jpmorgan Chase & CO Summit Therapeutics Inc. Transaction History

Jpmorgan Chase & CO

  • $1.22 Trillion
  • Q3 2024

A detailed history of Jpmorgan Chase & CO transactions in Summit Therapeutics Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 162,649 shares of SMMT stock, worth $2.9 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
162,649
Previous 163,750 0.67%
Holding current value
$2.9 Million
Previous $1.28 Million 178.94%
% of portfolio
0.0%
Previous 0.0%

Shares

17 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Dec 26, 2024
SELL
$6.89 - $31.93 $7,585 - $35,154
-1,101 Reduced 0.67%
162,649 $3.56 Million
Q3 2024

Nov 08, 2024
SELL
$6.89 - $31.93 $7,585 - $35,154
-1,101 Reduced 0.67%
162,649 $3.56 Million
Q2 2024

Dec 26, 2024
BUY
$2.39 - $10.92 $2,631 - $12,022
1,101 Added 0.68%
163,750 $1.28 Million
Q2 2024

Aug 12, 2024
SELL
$2.39 - $10.92 $205,341 - $938,213
-85,917 Reduced 34.41%
163,750 $1.28 Million
Q1 2024

Dec 26, 2024
BUY
$2.55 - $5.07 $221,895 - $441,181
87,018 Added 53.5%
249,667 $1.03 Million
Q1 2024

May 10, 2024
SELL
$2.55 - $5.07 $118,671 - $235,947
-46,538 Reduced 15.71%
249,667 $1.03 Million
Q4 2023

Dec 26, 2024
BUY
$1.67 - $2.83 $223,038 - $377,963
133,556 Added 82.11%
296,205 $773,000
Q4 2023

Feb 12, 2024
BUY
$1.67 - $2.83 $137,592 - $233,166
82,391 Added 38.53%
296,205 $773,000
Q3 2023

Nov 14, 2023
BUY
$1.54 - $2.42 $149,994 - $235,705
97,399 Added 83.67%
213,814 $399,000
Q2 2023

Aug 11, 2023
BUY
$1.32 - $2.81 $123,170 - $262,203
93,311 Added 403.87%
116,415 $292,000
Q1 2023

May 11, 2023
BUY
$1.38 - $5.41 $13,140 - $51,514
9,522 Added 70.11%
23,104 $40,000
Q4 2022

Feb 13, 2023
BUY
$0.68 - $5.31 $809 - $6,318
1,190 Added 9.6%
13,582 $58,000
Q3 2022

Nov 14, 2022
BUY
$0.89 - $1.63 $6,458 - $11,828
7,257 Added 141.32%
12,392 $15,000
Q2 2022

Aug 11, 2022
SELL
$0.92 - $2.38 $17,341 - $44,860
-18,849 Reduced 78.59%
5,135 $6,000
Q1 2022

May 11, 2022
SELL
$2.0 - $3.45 $19,006 - $32,785
-9,503 Reduced 28.38%
23,984 $58,000
Q4 2021

Feb 10, 2022
BUY
$2.45 - $5.64 $40,532 - $93,308
16,544 Added 97.65%
33,487 $90,000
Q3 2021

Nov 12, 2021
BUY
$4.83 - $8.27 $81,834 - $140,118
16,943 New
16,943 $85,000

Others Institutions Holding SMMT

# of Institutions
192
Shares Held
75.8M
Call Options Held
2.01M
Put Options Held
2.84M
View Full List

About Summit Therapeutics Inc.

SMMT Quotes by TradingView
  • Ticker SMMT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 201,215,008
  • Market Cap $3.59B
  • Description
  • Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecu...
More about SMMT
Track This Portfolio

Track Jpmorgan Chase & CO Portfolio

Follow Jpmorgan Chase & CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email